333PRibociclib (RIB) + letrozole (LET) in patients (pts)...

Annals of Oncology 2019 / 10 Vol. 30; Iss. Supplement

333PRibociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Cottu, P H, De Laurentiis, M, Marchetti, P, Coltelli, L, Califaretti, N, Debled, M, Patil, S, Evron, E, Duhoux, F P, Menon-Singh, L, Wu, J, Zhou, K, Salvador Bofill, J
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz242.028
Date:
October, 2019
File:
PDF, 74 KB
2019
Conversion to is in progress
Conversion to is failed